Actelion Ltd.
is a leading
biopharmaceutical
company focused
on the discovery,
development
and commercialization
of innovative drugs
for diseases
with significant
unmet medical needs.

European Commission grants marketing authorization for Uptravi (selexipag) in PAH

Jean-Paul Clozel, CEO: "Actelion has a
comprehensive portfolio of treatments across
the continuum of care in PAH that provide
long-term outcome benefits."

Jean-Paul Clozel, CEO: "Actelion has a
comprehensive portfolio of treatments across
the continuum of care in PAH that provide
long-term outcome benefits."

Global Actelion

Hotspot of possibilities

Actelion has subsidiaries in over 30 countries, covering all major pharmaceutical markets worldwide

Hotspot of possibilities

Actelion has subsidiaries in over 30 countries, covering all major pharmaceutical markets worldwide

Shareprice

ATLN SIX Swiss Exchange

Shareprice
At 17:31:37 CET 25/05/2016
CHF 160,20Up Down image
-0,10 (-0,06%)